Learn what challenges exist when developing biologic drugs to be efficacious but safe and how novel analytical techniques, like surface plasmon resonance, can help circumvent these issues and optimize development.
Many biopharmaceutical companies have made significant investments in research and the clinical development of gene therapies. For those working to develop and bring new gene therapy treatments to market, it is critical to select the right contract research organization (CRO) to conduct these studies. Here are three helpful strategies to follow when selecting a CRO partner.
An outlook on the market shows plasma fractionators will have to look to innovation and other opportunities for supply, in order to meet the needs of patients.
This whitepaper discusses the importance of understanding how critical process parameters can impact a product’s critical quality attributes, and how a systematic approach with validated SPR assays can help in this respect.
Critical quality attributes (CQA) are fundamental to regulatory compliance and in drug development and manufacturing. Find out how surface plasmon resonance has been applied for protein characterization of antibody effector function.
Critical quality attributes (CQA) are fundamental to regulatory compliance and typically include data on how the candidate interacts with target proteins, size, and purity. In addition, information on process related CQA such as protein integrity, homogeneity, presence of host cell proteins, and DNA is required. This poster booklet provides a snapshot on how different analytical technologies have been used to look into aspects related to the efficacy, stability, and safety of therapeutic candidates.
To address the growing need for speed and efficiency in viral vector manufacturing, GE developed a process for adenovirus manufacturing that not only meets regulatory requirements but is also scalable.
Cell-free synthesis systems are well suited to manufacture at the point of treatment, yet there are several challenges transitioning to this more efficient model for the future of medicine.
Frost & Sullivan recently invited academic and industry leaders in neuroscience research to participate in a unique thought leadership forum, our Virtual Think Tank series, titled Biomarkers for the Brain. This forum brought together leading minds involved in the study of biomarkers of central nervous system (CNS) diseases and disorders. The Virtual Think Tank stirred discussion about technological advancements in the field, current progress, future implications of the research and development occurring today, plus unmet needs in tools, key challenges that still remain, and expectations for future usage of biomarkers in CNS diseases.
Industry experts joined a panel at Frost & Sullivan's Virtual Think Tank recently to discuss the current state of immunotherapies, implications of research and development occurring today, key challenges, and future approaches to the targeted use of the immune system in cancer treatment. Read their thoughts on immunotherapies and the critical role for the immune system to play, especially in the advanced stages of cancer, since traditional standard-of-care therapies do often work fairly well.
